Prostatype Genomics Ab (PGABF)

$0.13 +0.05 (57.88%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 100
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Prostatype Genomics AB manufactures, markets, and sells prognostic gene tests. The company offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, and tumor stage, as well as calculates the P-score. Its test is based on database containing prostate cancer patients; and provides decision support for patients and doctors when making a treatment decision. The company was incorporated in 2007 and is headquartered in Solna, Sw...

Phone: 46 08 20 87 00
Address:
Gustaf III:s Boulevard 34, Solna, Sweden
Dennizz
Dennizz Aug. 17 at 2:12 PM
$TNXP Also check out $PGABF huge trigger before the year end Medicare aproval🚀🚀
0 · Reply
Dennizz
Dennizz Aug. 17 at 1:19 PM
$PGABF 🇺🇸 Could this be one of Europe’s most overlooked MedTech microcaps? $PGABF A tiny Swedish precision-medicine company Prostatype valued at only $5 million has developed a fully commercialized genomic test for prostate cancer, and is now awaiting a potentially transformational Medicare reimbursement decision in the U.S before year end🔥 $BNGO $INO $TNXP $ATOS.X
1 · Reply
thetradeguyfrom
thetradeguyfrom Aug. 16 at 6:29 PM
$PGABF I think this could be a very interesting time to get in early. The CEO said this in an interview just one month ago, which makes the current situation especially interesting.
0 · Reply
B2iDigital
B2iDigital Jun. 19 at 2:55 PM
Prostatype Genomics AB (OTCQB: $PGABF | Nasdaq Stockholm: $PROGEN) opens day two of the Life Sciences Virtual Investor Forum, co-hosted by Virtual Investor Conferences and Zacks Small Cap Research, at 9:30 AM ET on Thursday, June 25, 2026. The Life Sciences Virtual Investor Forum is a B2i Digital Featured Conference. For more details, please visit: https://b2idigital.com/vic-june-25th-life-sciences-virtual-investor-forum To register and view the presentation: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5389325/prostatype-genomics-ab-otcqb-pgabf-nasdaq-stockholm-progen?utm_source=b2i&utm_medium=marketing&utm_campaign=0624LifeSciencesForumVIC Request a one-on-one meeting: https://app.axleaccess.com/public/events/636943bb-55cb-4a39-81b5-f658175de392?token=7b91921e-7b44-4da7-be93-ea5c37a5ed76 Fredrik Rickman, CEO, presents for Prostatype Genomics. He holds a B.Sc. in Business Administration and Economics from the University of Lund and brings more than 30 years of international life science industry experience in leadership positions. Prostate cancer is one of the most common forms of cancer, with approximately 1.3 million men diagnosed annually. Prostatype Genomics specializes in the development, manufacturing, and marketing of Prostatype, a prognostic genetic test that provides a comprehensive assessment of the aggressiveness of prostate cancer. Learn more at https://www.prostatypegenomics.com/investor-relations/. Virtual Investor Conferences is an OTC Markets Group Inc. property. Learn more at www.virtualinvestorconferences.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. B2i Digital is the Official Marketing Partner of Virtual Investor Conferences. Content is informational only and is not investment advice. B2i Digital is not a broker-dealer or investment adviser.
1 · Reply
B2iDigital
B2iDigital Mar. 10 at 7:34 PM
The B2i Digital team is pleased to announce that Prostatype Genomics AB (OTCQB: $PGABF | Nasdaq Stockholm: $PROGEN) is participating in the Life Sciences Virtual Investor Forum, co-hosted by Virtual Investor Conferences and Zacks Small Cap Research, on Thursday, March 12, 2026, at 10:00 AM EDT. The Life Sciences Virtual Investor Forum is a B2i Digital Featured Conference. For more details, please visit: https://b2idigital.com/otc-life-sciences-virtual-investor-forum Virtual Investor Conferences brings together public companies and a global audience of retail and institutional investors for live executive presentations, Q&A sessions, and on-demand replays. The platform is open to public companies listed on NYSE, Nasdaq, TSX, CSE, ASX, and the OTC Markets. Prostatype Genomics AB specializes in the development, manufacturing, and marketing of Prostatype, a prognostic genetic test that provides a comprehensive assessment of prostate cancer aggressiveness. Prostate cancer is among the most common forms of cancer worldwide, with approximately 1.3 million men diagnosed annually. Presenting on behalf of Prostatype Genomics will be Fredrik Rickman, Chief Executive Officer, who has led the company since 2017. He holds a B.Sc. in Business Administration and Economics from the University of Lund and brings more than 30 years of international life science industry experience in senior roles with a focus on operational and organizational growth. To register for this presentation, visit: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5259454/prostatype-genomics-ab-otcqb-pgabf-nasdaq-stockholm-progen?utm_source=b2i&utm_medium=marketing&utm_campaign=0326LifeSciencesVIC For more information about Prostatype Genomics, visit: https://www.prostatypegenomics.com/investor-relations/ Content about any specific company was provided and approved by that company or is available in the public domain. B2i Digital, Inc. has not independently verified the accuracy of the information contained herein. The content contained herein is informational only, and no content contained herein shall be considered an offer to solicit the sale of any security or make a recommendation to purchase a security. B2i Digital is not a broker-dealer or investment adviser.
1 · Reply
Latest News on PGABF
No data available.
Dennizz
Dennizz Aug. 17 at 2:12 PM
$TNXP Also check out $PGABF huge trigger before the year end Medicare aproval🚀🚀
0 · Reply
Dennizz
Dennizz Aug. 17 at 1:19 PM
$PGABF 🇺🇸 Could this be one of Europe’s most overlooked MedTech microcaps? $PGABF A tiny Swedish precision-medicine company Prostatype valued at only $5 million has developed a fully commercialized genomic test for prostate cancer, and is now awaiting a potentially transformational Medicare reimbursement decision in the U.S before year end🔥 $BNGO $INO $TNXP $ATOS.X
1 · Reply
thetradeguyfrom
thetradeguyfrom Aug. 16 at 6:29 PM
$PGABF I think this could be a very interesting time to get in early. The CEO said this in an interview just one month ago, which makes the current situation especially interesting.
0 · Reply
B2iDigital
B2iDigital Jun. 19 at 2:55 PM
Prostatype Genomics AB (OTCQB: $PGABF | Nasdaq Stockholm: $PROGEN) opens day two of the Life Sciences Virtual Investor Forum, co-hosted by Virtual Investor Conferences and Zacks Small Cap Research, at 9:30 AM ET on Thursday, June 25, 2026. The Life Sciences Virtual Investor Forum is a B2i Digital Featured Conference. For more details, please visit: https://b2idigital.com/vic-june-25th-life-sciences-virtual-investor-forum To register and view the presentation: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5389325/prostatype-genomics-ab-otcqb-pgabf-nasdaq-stockholm-progen?utm_source=b2i&utm_medium=marketing&utm_campaign=0624LifeSciencesForumVIC Request a one-on-one meeting: https://app.axleaccess.com/public/events/636943bb-55cb-4a39-81b5-f658175de392?token=7b91921e-7b44-4da7-be93-ea5c37a5ed76 Fredrik Rickman, CEO, presents for Prostatype Genomics. He holds a B.Sc. in Business Administration and Economics from the University of Lund and brings more than 30 years of international life science industry experience in leadership positions. Prostate cancer is one of the most common forms of cancer, with approximately 1.3 million men diagnosed annually. Prostatype Genomics specializes in the development, manufacturing, and marketing of Prostatype, a prognostic genetic test that provides a comprehensive assessment of the aggressiveness of prostate cancer. Learn more at https://www.prostatypegenomics.com/investor-relations/. Virtual Investor Conferences is an OTC Markets Group Inc. property. Learn more at www.virtualinvestorconferences.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. B2i Digital is the Official Marketing Partner of Virtual Investor Conferences. Content is informational only and is not investment advice. B2i Digital is not a broker-dealer or investment adviser.
1 · Reply
B2iDigital
B2iDigital Mar. 10 at 7:34 PM
The B2i Digital team is pleased to announce that Prostatype Genomics AB (OTCQB: $PGABF | Nasdaq Stockholm: $PROGEN) is participating in the Life Sciences Virtual Investor Forum, co-hosted by Virtual Investor Conferences and Zacks Small Cap Research, on Thursday, March 12, 2026, at 10:00 AM EDT. The Life Sciences Virtual Investor Forum is a B2i Digital Featured Conference. For more details, please visit: https://b2idigital.com/otc-life-sciences-virtual-investor-forum Virtual Investor Conferences brings together public companies and a global audience of retail and institutional investors for live executive presentations, Q&A sessions, and on-demand replays. The platform is open to public companies listed on NYSE, Nasdaq, TSX, CSE, ASX, and the OTC Markets. Prostatype Genomics AB specializes in the development, manufacturing, and marketing of Prostatype, a prognostic genetic test that provides a comprehensive assessment of prostate cancer aggressiveness. Prostate cancer is among the most common forms of cancer worldwide, with approximately 1.3 million men diagnosed annually. Presenting on behalf of Prostatype Genomics will be Fredrik Rickman, Chief Executive Officer, who has led the company since 2017. He holds a B.Sc. in Business Administration and Economics from the University of Lund and brings more than 30 years of international life science industry experience in senior roles with a focus on operational and organizational growth. To register for this presentation, visit: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5259454/prostatype-genomics-ab-otcqb-pgabf-nasdaq-stockholm-progen?utm_source=b2i&utm_medium=marketing&utm_campaign=0326LifeSciencesVIC For more information about Prostatype Genomics, visit: https://www.prostatypegenomics.com/investor-relations/ Content about any specific company was provided and approved by that company or is available in the public domain. B2i Digital, Inc. has not independently verified the accuracy of the information contained herein. The content contained herein is informational only, and no content contained herein shall be considered an offer to solicit the sale of any security or make a recommendation to purchase a security. B2i Digital is not a broker-dealer or investment adviser.
1 · Reply